Monitor for future ESPP purchase periods to gauge dilution timing, but this filing is routine and unlikely to move the stock. No immediate trading action warranted.
Price Chart
Executive Summary
Aligos Therapeutics filed an 8-K reporting the results of its 2026 Annual Meeting, where stockholders approved an amendment to the 2020 Employee Stock Purchase Plan. The amendment adds 500,000 new shares and eliminates the evergreen provision, capping total reserved shares at 694,714. This is a routine administrative filing with no material financial impact.
Key Facts
- Stockholders approved an amendment to the 2020 Employee Stock Purchase Plan, adding 500,000 shares for issuance and eliminating the evergreen provision.
- Total shares reserved under the amended ESPP are fixed at 694,714.
- All five proposals at the annual meeting passed, including election of directors, ratification of auditor, and advisory votes on executive compensation.
- Bridget Martell and Carole Nuechterlein were elected as Class III directors with over 95% of votes cast in favor (excluding broker non-votes).
Financial Impact
No direct financial impact; potential dilution from ESPP purchases is modest (500k shares, ~9.3% of outstanding shares) but typical for employee plans.
Risk Factors
- Potential modest dilution as new ESPP shares are issued in future offering periods.
- No other material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-285426 |
| Document: d70452dex101.htm | 0001193125-26-285426 |
| Document: 0001193125-26-285426-index-headers.html | 0001193125-26-285426 |
| Document: 0001193125-26-285426-index.html | 0001193125-26-285426 |
| Document: 0001193125-26-285426.txt | 0001193125-26-285426 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.65 (−15.61%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.65 (−14.36%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.65 (−16.96%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.65 (−39.30%) |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.65 (−37.33%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.65 (−30.18%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.65 (−33.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers